Background: Nitric oxide (NO) has emerged as an important neurotransmitter involved in the control of the neuroendocrine function. NO acts at hypothalamic, pituitary, and gonadal levels. Previous data from our laboratory showed that blockade of NO generation, after systemic administration of a NO synthase inhibitor (Nω-nitro-arginine methyl ester, NAME), increased the luteinizing hormone (LH) secretion in intact and ovariectomized females, whereas a blockade of spontaneous and steroid-induced LH and prolactin surges after NO synthase inhibition has been also described. Methods and Results: Adult male rats were implanted with chronic intra-auricular cannulae and 5 days later sampled at 15-min intervals during 6 h (10.00–16.00 h). Administration of NAME (40 mg/kg at 08.00 and 13.00 h) stimulated significantly (p ≤ 0.01) the LH secretion, increasing LH pulse amplitude (0.58 ± 0.14 vs. 0.08 ± 0.01 ng/ml in controls), mean LH levels (0.64 ± 0.15 vs. 0.15 ± 0.03 ng/ml in controls), and area under curve (239 ± 56 vs. 57 ± 13 in controls). This effect was blocked by coadministration of sodium nitroprusside (SNP), a NO donor (0.5 mg/kg). The action of NAME was observed 3 h after administration, in contrast to the earlier response detected in female rats, and it appeared selective for LH, as prolactin and growth hormone secretion remained unchanged. Further analysis was carried out to determine whether the effect of NAME on the LH secretion was indirect and mediated by changes in testosterone release. To this end, adult male rats were decapitated 2 h after administration of NAME (40 mg/kg), SNP (0.5 mg/kg), or L-nitro-arginine methyl ester (L-AME), a substrate for NOS (1 g/kg). The serum testosterone concentrations were unchanged after NAME administration, but inhibited by SNP and L-AME. Finally, the effect of NAME and SNP on in vitro testosterone secretion was analyzed. NAME (10 mM) did not affect basal testosterone production, but inhibited the human chorionic gonadotropin stimulated testosterone secretion. Conclusions: These data strongly suggest that the stimulatory effect of NAME on LH secretion is not due to an inhibition of testosterone release and is exerted at the hypothalamic-pituitary level.

Keywords:
Nitric oxide, Luteinizing hormone, Prolactin, Growth hormone, Male rat, Testosterone
1.
Nelson RJ, Kriegsfeld LJ, Dawson VL, Dawson TM: Effects of nitric oxide on neuroendocrine function and behavior. Front Neuroendocrinol 1997;18:463–491.
2.
Bredt DS, Hwang PM, Snyder SH: Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature 1990;347:768–770.
3.
Ceccatelli S, Hulting AL, Zhang X, Gustafsson L, Villar M, Hökfelt T: Nitric oxide synthase in the rat anterior pituitary gland and the role of nitric oxide in regulation of luteinizing hormone secretion. Proc Natl Acad Sci USA 1993;90:11292–11296.
4.
Yamada K, Xu ZQ, Zhang X, Gustafsson L, Hulting AL, de Vente J, Steinbusch HWM, Hökfelt T: Nitric oxide synthase and cGMP in the anterior pituitary gland: Effect of a GnRH antagonist and nitric oxide donors. Neuroendocrinology 1997;65:147–156.
5.
Moretto M, López FJ, Negro-Vilar A: Nitric oxide regulates luteinizing hormone-releasing hormone. Endocrinology 1993;133:2399–2402.
6.
López FJ, Moretto M, Merchentaler I, Negro-Vilar A: Nitric oxide is involved in the genesis of pulsatile LHRH secretion from immortalized LHRH neurons. J Neuroendocrinol 1997;9:647–654.
7.
Rettori V, Belova N, Dees WL, Nyberg CL, Gimeno M, McCann SM: Role of nitric oxide in the control of luteinizing hormone-releasing hormone release in vivo and in vitro. Proc Natl Acad Sci USA 1993;90:10130–10134.
8.
Bonavera JJ, Kalra PS, Kalra SP: L-Arginine/nitric oxide amplifies the magnitude and duration of the luteinizing hormone surge induced by estrogen: Involvement of neuropeptide Y. Endocrinology 1996;137:1956–1962.
9.
Sortino MA, Aleppo G, Scapagnini U, Canonico PL: Involvement of nitric oxide in the regulation of gonadotropin-releasing hormone release from the GT1-1 neuronal cell line. Endocrinology 1994;134:1782–1787.
10.
Seilicovich A, Duvilanski BH, Pisera D, Theas S, Gimeno M, Rettori V, McCann SM: Nitric oxide inhibits hypothalamic luteinizing hormone-releasing hormone release by releasing γ-aminobutyric acid. Proc Natl Acad Sci USA 1995;92:3421–3424.
11.
Pinilla L, González D, Tena-Sempere M, Aguilar E: Nitric oxide (NO) stimulates gonadotropin secretion in vitro through a calcium-dependent, cGMP-independent mechanism. Neuroendocrinology 1998;68:180–186.
12.
Yu WH, Walczewska A, Karanth AS, McCann SM: Nitric oxide mediates leptin-induced luteinizing hormone-releasing hormone (LHRH) and LHRH and leptin-induced LH release from the pituitary gland. Endocrinology 1997;138:5055–5058.
13.
Adams ML, Nock B, Truong R, Cicero TJ: Nitric oxide control of steroidogenesis: Endocrine effects of NG-nitro-L-arginine and comparisons to alcohol. Life Sci 1992;50:35–40.
14.
Adams ML, Meyer ER, Sewing BN, Cicero TJ: Effects of nitric oxide-related agents on rat testicular function. J Pharmacol Exp Ther 1994;269:230–237.
15.
Gaytàn F, Bellido C, Aguilar R, Morales C, van Roojen N, Aguilar E: Role of the testis in the response of the pituitary-testicular axis to nitric oxide related agents. Eur J Endocrinol 1997;137:301–308.
16.
Pinilla L, Tena-Sempere M, González D, Aguilar E: The role of nitric oxide in the control of basal and LHRH-stimulated LH secretion. J Endocrinol Invest 1999;23:340–348.
17.
Bonavera JJ, Sahu A, Kalra PS, Kalra SP: Evidence that nitric oxide may mediate the ovarian steroid-induced luteinizing hormone surge: Involvement of excitatory amino acids. Endocrinology 1993;133:2481–2487.
18.
Bonavera JJ, Sahu A, Kalra PS, Kalra SP: Evidence in support of nitric oxide (NO) involvement in the cyclic release of prolactin and LH surges. Brain Res 1994;660:175–179.
19.
González D, Aguilar E: In vitro, nitric oxide (NO) stimulates LH secretion and partially prevents the inhibitory effect of dopamine on PRL release. J Endocrinol Invest 1999;22:772–780.
20.
Tena-Sempere M, González D, Aguilar E: Involvement of endogenous nitric oxide in the control of pituitary responsiveness to different elicitors of growth hormone release in prepubertal rats. Neuroendocrinology 1996,64:146–152.
21.
Grenwood FC, Hunter WM, Glover JS: The preparation of 131-I-labelled human growth hormone of high specific radioactivity. Biochem J 1963;89:114–123.
22.
Rodrígez-Padilla M, Bellido C, Pinilla L, Aguilar E: Secretion of LH in spontaneously hypertensive rats. J Endocrinol 1987;113:255–260.
23.
Welch C, Watson ME, Poth M, Hong T, Francis GL: Evidence to suggest nitric oxide is an interstitial regulator of Leydig cell steroidogenesis. Metabolism 1995,44:234–238.
24.
Pinillar L, González MD, Tena-Sempere M, Aguilar R, Aguilar E: Effects of N-methyl-D-aspartate and kainic acid on prolactin secretion in prepubertal female rats. Eur J Endocrinol 1996;135:464–468.
25.
Aguilar E, Tena-Sempere M, Aguilar R, González D, Pinilla L: Interactions between N-methyl-D-aspartate, nitric oxide and serotonin in the control of prolactin secretion in prepubertal male rats. Eur J Endocrinol 1997;137:99–106.
26.
Pinilla L, González D, Tena-Sempere M, Aguilar R, Aguilar E: Mechanisms of inhibitory action of kainic acid on prolactin secretion in male rats. J Endocrinol 1996;151:159–167.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.